Floatz logo

Buprenorphine

Opioid Use Disorder, Moderate

Gavin BartSmall moleculePhase 2/3Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Opioid Use Disorder, Moderate cohort.

Asset / SponsorPhaseRating
Buprenorphine
Erin Winstanley
Phase 4BBB
Buprenorphine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 4BB
LIDOCAINE
University Medical Centre Ljubljana
Phase 4BB
17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
University of California, San Francisco
Phase 4BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Denver Health and Hospital Authority
Phase 4BB

View all 39 →

Same molecule, other indications

Buprenorphine is also rated in:

opiate dependenceDormant
BBB
Indicative ·
76 / 100
View asset →
osteoarthritisDormant
BBB
Indicative ·
75 / 100
View asset →
Low Back PainDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →